Dyax Corp. DYAX, a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced that it has been named one of the Top Places to Work in Massachusetts by The Boston Globe for the second year in a row.
"We are honored to be recognized again by The Boston Globe as one of the top places to work," said Gustav Christensen, President and Chief Executive Officer of Dyax. "At Dyax, we understand the importance of cultivating a positive atmosphere and hope to continue to inspire our team members in all of their professional endeavors. I extend my sincere thanks to all the employees of Dyax for their hard work and dedication."
The Boston Globe Top Places to Work 2015 magazine was published in The Boston Sunday Globe on November 15 and will also be featured on BostonGlobe.com/topplaces. Dyax ranked 2nd out of all Medium-sized Massachusetts employers, defined as companies with 100-249 employees.
The rankings in the Top Places to Work are based on confidential survey information collected by Workplace Dynamics, an independent company specializing in employee engagement and retention, from nearly 77,000 individuals at 357 Massachusetts organizations.
About Dyax
Dyax is a biopharmaceutical company focused on
the development and commercialization of novel biotherapeutics for unmet
medical needs. The Company is developing DX-2930,
a fully human monoclonal antibody, for the prevention of HAE attacks.
Additionally, Dyax markets KALBITOR®
(ecallantide) for the treatment of acute attacks of HAE in patients
12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax's proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company's CYRAMZA (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.
Disclaimer
This press release contains forward-looking
statements. Statements that are not historical facts are based on Dyax's
current expectations, beliefs, assumptions, estimates, forecasts and
projections about the industry and markets in which Dyax operates. The
statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and assumptions,
which are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed in such forward-looking
statements because of risks, uncertainties and assumptions involved in
any future projections. There are many factors that could cause actual
results to differ from these forward-looking statements, including:
risks and uncertainties relating to the clinical development of DX-2930;
Dyax's dependence on the expertise, effort, priorities and contractual
obligations of third parties in the development of DX-2930 and in the
marketing, sales and distribution of KALBITOR; competition from new and
existing treatments for HAE; the uncertainty of patent and intellectual
property protection relating to DX-2930, KALBITOR and the LFRP; Dyax's
dependence on licensees and collaborators for development, clinical
trials, manufacturing, sales and distribution of product candidates in
the LFRP; uncertainties as to whether one or more product candidates in
the LFRP will achieve development and regulatory milestones and be
commercialized and generate royalties; uncertainties regarding Lilly's
ability to successfully market CYRAMZA for the treatment of advanced
gastric cancer; and other risk factors described or referred to in Item
1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and
other periodic reports filed with the Securities and Exchange
Commission. Dyax cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These statements
speak only as of the date of this release, and Dyax undertakes no
obligations to update or revise these statements, except as may be
required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
CYRAMZA is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151117005270/en/
Dyax Corp.
Jennifer Robinson, 617-250-5741
Director, Investor
Relations and Corporate Communications
jrobinson@dyax.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.